DXCM
DEXCOM, INC.NasdaqResearch view
Healthcare · Surgical & Medical Instruments & Apparatus · Large-cap · SEC EDGAR FY 2025-12-31
Price history
Chart: TradingView’s own feed · page prices: 1D EOD🔒 Click to interact · scroll moves the page
Snapshot
SEC EDGAR · FY 2025-12-31SectorHealthcare
Market Cap$32.6B
Enterprise Value$31.7B
Income$836.3M
Sales$4.7B
Book/sh$7.28
Cash/sh$2.44
Dividend TTM—
Payout—
Employees—
IPO—
Quick Ratio1.59
Current Ratio1.88
Debt/Eq0.00
EPS (ttm)$2.09
EPS this Y47.2%
EPS past 3/5Y36.6%
Sales past 3/5Y17.0%
EPS Y/Y TTM47.2%
Sales Y/Y TTM15.6%
Shs Outstand377.36M
ROA13.2%
ROE30.5%
ROIC38.3%
Gross Margin60.1%
Oper. Margin19.6%
Profit Margin17.9%
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.
Revenue & Earnings — fiscal year
$2.4B
2021
$2.9B
2022
$3.6B
2023
$4.0B
2024
$4.7B
2025
Financials — annual
SEC EDGAR · last 5 FY · tap a row to explain it| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2.4B | $2.9B | $3.6B | $4.0B | $4.7B |
| Gross Profit | $1.7B | $1.9B | $2.3B | $2.4B | $2.8B |
| Operating Income | $265.8M | $391.2M | $597.7M | $600.0M | $911.8M |
| Net Income | $216.9M | $341.2M | $541.5M | $576.2M | $836.3M |
| Diluted EPS | $0.53 | $0.82 | $1.30 | $1.42 | $2.09 |
| Operating Cash Flow | $442.5M | $669.5M | $748.5M | $989.5M | $1.4B |
| Free Cash Flow | $53.3M | $304.7M | $511.9M | $630.7M | $1.1B |
Deep dive
Computed from the SEC EDGAR multi-year statementsOperating leverage — margins
GrossOperatingNet
FY25 cash-flow waterfall
Capital-light: capex is $363.5M against $1.4B operating cash
COMMUNITY · $DXCM0 theses
POST YOUR TAKE →Related Stocks
Click to exploreSame Industry · Surgical & Medical Instruments & Apparatus
Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.